Long term results of three anti-vascular endothelial growth factor agents in pachychoroid neovasculopathy

Autor: Buğra Karasu, Yusuf Berk Akbas, Mert Kaskal, Aslan Aykut, Ali Rıza Cenk Celebi
Přispěvatelé: Karasu B., Akbas Y. B., KAŞKAL M., Aykut A., ÇELEBİ A. R. C.
Rok vydání: 2022
Předmět:
Sağlık
Toksikoloji ve Mutajenez
chronic central serous chorioretinopathy
Pharmaceutical Toxicology
Health
Toxicology and Mutagenesis
TOKSİKOLOJİ
Visual Acuity
Angiogenesis Inhibitors
Endothelial Growth Factors
Sağlık Bilimleri
Toxicology
THERAPY
Göz Hastalıkları ve Cerrahisi
Clinical Medicine (MED)
Oftalmoloji
Eye Diseases and Surgery
Surgery Medicine Sciences
Klinik Tıp (MED)
anti-vascular endothelial growth factor agents
Pharmacology
Toxicology and Pharmaceutics (miscellaneous)
PHARMACOLOGY & TOXICOLOGY
Pachychoroid neovasculopathy
Klinik Tıp
Temel Bilimler
GÖZ HASTALIKLARI
Life Sciences
General Medicine
Middle Aged
Toksikoloji
Tıp
Bevacizumab
Farmasötik Toksikoloji
Intravitreal Injections
Cerrahi Tıp Bilimleri
Farmakoloji ve Toksikoloji
Physical Sciences
COHERENCE TOMOGRAPHY ANGIOGRAPHY
Medicine
Natural Sciences
Tomography
Optical Coherence
Adult
Life Sciences (LIFE)
subfoveal choroidal thickness
Meslek Bilimleri
Yaşam Bilimleri
Health Sciences
Professional Sciences
OPHTHALMOLOGY
Humans
Farmakoloji
Toksikoloji ve Eczacılık (çeşitli)
Eczacılık
Aged
Retrospective Studies
Choroid
AFLIBERCEPT
CLINICAL MEDICINE
RANIBIZUMAB
Pharmacology and Therapeutics
Optometri
Fizik Bilimleri
Yaşam Bilimleri (LIFE)
Follow-Up Studies
Optometry
Zdroj: Cutaneous and Ocular Toxicology. 41:145-154
ISSN: 1556-9535
1556-9527
Popis: Purpose To assess morphological changes and visual results in eyes with pachychoroid neovasculopathy (PNV) that underwent different intravitreal anti-vascular endothelial growth factor (VEGF) agents. Materials and methods This is a retrospective, observational, comparative study that included 76 PNV eyes in 76 patients that were allocated to three groups according to the monotherapy injection procedure, as follows: the intravitreal bevacizumab (IVB) group, intravitreal ranibizumab (IVR) group, and intravitreal aflibercept (IVA) group. Central macular thickness (CMT), best-corrected visual acuity (BCVA), and subfoveal choroidal thickness (SFCT) were measured at baseline, after treatment 1st month, 3rd month, 6th month, and 12th month, and at the final post-treatment examination. Results Mean age of the patients was 57.31 +/- 5.91 years (range: 34-67 years). The mean duration of follow-up was 31.50 +/- 12.91 months (range: 13-60 months). The IVB group included 30 eyes, the IVR group included 22 eyes, and the IVA group included 24 eyes. There weren\"t any significant differences in BCVA changes between the groups at any post-baseline measurement time point. Although CMT did not change significantly in the IVB group from baseline to the final follow-up visit (baseline: 376.33 +/- 86.31 mu m; final visit: 340.80 +/- 122.70 mu m) (p = 0.172), CMT did change significantly in the IVA group (baseline: 383.41 +/- 131.83 mu m; final visit: 297.33 +/- 103.81 mu m) (p = 0.029) and IVR group (baseline: 379.18 +/- 97.93 mu m; final visit: 335.72 +/- 111.45 mu m) (p = 0.041). SFCT decreased significantly in the IVR and IVA groups (p = 0.015 and p < 0.001, respectively). The mean number of injections was 12.06 +/- 4.72 (range: 6-20) in the IVB group, 11.81 +/- 3.31(range: 7-17) in the IVR group, and 7.16 +/- 3.15 (range: 4-13) in the IVA group (p = 0.004). Conclusion All three anti-VEGFs were effective in terms of visual results in patients with PNV. Patients treated with IVA required fewer injections than those treated with IVB or IVR. Furthermore, IVR and IVA treatment significantly decreased SFCT, whereas IVB did not.
Databáze: OpenAIRE
Externí odkaz: